Jianwei (Jerry) Fang, Xiaoyu (Arthur) Jin and Haoyi Sun of Zhong Lun Law Firm discuss the reasons behind, and the implications of, Illumina’s inclusion in China’s Unreliable Entity List, as well as compliance recommendations for multinational corporations
China strengthens Anti-Foreign Sanctions Law in response to U.S. restrictions; Chinese firms move production facilities overseas amidst key economic changes; and China introduces regulations to protect interests in overseas IP disputes
Multinationals must comply with new Chinese labeling requirements while the U.S. and EU have other specifications; A second Chinese court ruling affirms AI-generated images have copyright protection; and Supreme People’s Court cracks down on fraudulent behavior of prepayment service providers
Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
Chinese EV maker Geely expands into Brazil through a partnership with France’s Renault; The parent company of Calvin Klein and Tommy Hilfiger is blacklisted by China; and Canadian Solar is sued by China’s Trina Solar over patent infringement.
China increases regulatory framework for the pharma and life sciences sectors; Chinese authorities intervene to regulate VC funds management; and internet content providers could face stricter scrutiny on military-related content.
The sudden rise of DeepSeek AI has prompted regulators’ concerns over its processing of data; the EU plans to ensure e-commerce platforms are compliant with its laws; and U.S.-China tensions are pushing China-focused private equity funds to expand beyond China.
Data platforms that look into supply chains benefit from worsening U.S.-China trade relations; China issues first comprehensive guidelines on anti-corruption compliance for the healthcare sector; and complaints have been filed against TikTok, Shein, and AliExpress alleging they are transferring EU personal data to Chinese authorities in violation of GDPR rules.
In 2024, the U.S. continued placing wide-ranging restrictions on Chinese interests. What made that year different was the impact those restrictions have on third countries. Charles Wu of Clyde & Co reviews the legislative changes, and offers practical insights into their potential impact with a focus on third countries, and the path forward in 2025
